These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.
周三，强生公司（纽交所：JNJ）公布了超出预期的第二季度收益。
The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion, according to data from Benzinga Pro.
据Benzinga Pro的数据显示，该公司发布了每股调整后的2.82美元的EPS，同比增长10.2％，超过了2.70美元的共识预期。这家制药巨头的销售额为224.5亿美元，同比增长4.3％，超过了223.1亿美元的共识预期。
"With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth," said Joaquin Duato, Chairman and CEO.
董事长兼首席执行官华金·杜阿托（Joaquin Duato）表示：“在强大的管道、即将到来的RYBREVANt和TREMFYA的监管里程碑、Shockwave的整合以及新推出的产品，包括ACUVUE OASYS MAX 1-Day隐形眼镜和我们的VARIPULSE平台的持续扩展下，我们为近期和长期的增长奠定了坚实的基础。”
Johnson & Johnson raised fiscal year 2024 operational sales guidance to $89.2 billion-$89.6 billion versus prior guidance of $88.7 billion-$89.1 billion.
强生公司将2024财年运营销售指引上调至892亿美元-896亿美元，上次指引为887亿美元-891亿美元。
The company said it expects fiscal year 2024 adjusted EPS guidance of $9.97–$10.07, down from prior guidance of $10.57–$10.72 versus the consensus of $10.01, to reflect the impact of recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
该公司表示，预计2024财年调整后的EPS指引为9.97美元-10.07美元，低于先前的10.57美元-10.72美元，以反映Shockwave Medical、Proteologix和NM26 Bispecific Antibody的最新收购对业绩的影响。
Johnson & Johnson shares gained 0.1% to trade at $156.72 on Thursday.
周四，强生公司股票上涨0.1％，交易价格为156.72美元。
These analysts made changes to their price targets on Johnson & Johnson following the announcement.
这些分析师根据公告对强生公司的价格目标进行了调整。
- Morgan Stanley analyst Terence Flynn maintained Johnson & Johnson with an Equal-Weight rating and boosted the price target from $167 to $169.
- TD Cowen analyst Joshua Jennings maintained the stock with a Buy rating, while cutting the price target from $195 to $185.
- RBC Capital analyst Shagun Singh reiterated Johnson & Johnson with an Outperform rating and maintained a price target of $175.
- 摩根士丹利分析师Terence Flynn维持强生公司的等重评级，并将价格目标从167美元上调至169美元。
- TD Cowen分析师Joshua Jennings保持买入评级，但将价格目标从195美元下调至185美元。
- RBC Capital分析师Shagun Singh重申强生公司的跑赢大盘评级，并维持175美元的价格目标。
Read This:
阅读更多：
- PodcastOne And 2 Other Stocks Under $2 Insiders Are Buying
- PodcastOne和其他两只股票被内部人员买入，价格低于2美元。